|
業務類別
|
-- |
|
業務概覽
|
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US. |
| 公司地址
| 535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000 |
| 電話號碼
| +61 396604900 |
| 傳真號碼
| +61 396604999 |
| 公司網頁
| https://www.clinuvel.com |
| 員工數量
| 16 |
| Mr. Peter Vaughan |
Chief Financial Officer |
-- |
30/10/2026 |
| Dr. Philippe J. Wolgen, M.B.A.,M.D. |
Managing Director and Chief Executive Officer |
-- |
30/10/2026 |
| Mr. Lachlan Hay |
Chief Operating Officer |
-- |
30/10/2026 |
| Dr. Dennis Wright, PhD |
Chief Scientific Officer |
-- |
30/10/2026 |
|
|
| Dr. Karen Agersborg, M.D. |
Independent Director |
30/10/2026 |
| Ms. Susan Smith |
Independent Director |
30/10/2026 |
| Professor Jeffrey Rosenfeld, M.B.B.S.,M.D. |
Chairman of the Board |
30/10/2026 |
| Mr. Matthew Pringle, B.Com,F.C.A. |
Independent Director |
30/10/2026 |
| Dr. Pearl Grimes, M.D. |
Independent Director |
30/10/2026 |
| Mr. Guy Van Dievoet, L.L.B. |
Independent Director |
30/10/2026 |
|
|
|
|